(Q39405204)

11 September 2017

Outcome of older patients with acute myeloid leukemia in first relapse (English)

1 reference

11 September 2017

1 reference

acute myeloid leukemia

1 reference

1

1 reference

11 September 2017

6

Jean-Valère Malfuson

0 references

Nathalie Gachard

Nathalie Gachard

3

0 references

Bruno Quesnel

Bruno Quesnel

10

0 references

Sylvie Chevret

Sylvie Chevret

15

0 references

Claude Preudhomme

Claude Preudhomme

12

0 references

Pierre Fenaux

14

Pierre Fenaux

1 reference

11 September 2017

17

Hervé Dombret

1 reference

11 September 2017

5

Pascal Turlure

1 reference

11 September 2017

7

Cécile Pautas

1 reference

11 September 2017

13

Christine Terré

1 reference

11 September 2017

11

Karine Celli-Lebras

1 reference

11 September 2017

16

Sylvie Castaigne

1 reference

11 September 2017

8

Jean-Baptiste Micol

1 reference

11 September 2017

Claude Gardin

2

1 reference

PubMed ID

23749683

11 September 2017

Fathia Merabet

4

1 reference

PubMed ID

23749683

11 September 2017

Xavier Thomas

9

1 reference

11 September 2017

7 August 2013

1 reference

American Journal of Hematology

11 September 2017

1 reference

11 September 2017

88

1 reference

11 September 2017

9

1 reference

11 September 2017

758-764

1 reference

Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities

11 September 2017

1 reference

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse

21 January 2018

1 reference

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

21 January 2018

1 reference

FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype

21 January 2018

1 reference

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study

21 January 2018

1 reference

Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria

21 January 2018

1 reference

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial

21 January 2018

1 reference

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.

21 January 2018

1 reference

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

21 January 2018

1 reference

Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

21 January 2018

1 reference

FLT3/ITD AML and the law of unintended consequences

21 January 2018

1 reference

Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.

21 January 2018

1 reference

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial

21 January 2018

1 reference

Gemtuzumab ozogamicin: time to resurrect?

21 January 2018

1 reference

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

21 January 2018

1 reference

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

21 January 2018

1 reference

Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

21 January 2018

1 reference

Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia

21 January 2018

1 reference

Current and emerging strategies for the management of acute myeloid leukemia in the elderly

21 January 2018

1 reference

Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23498

1 reference

11 September 2017

1 reference

PubMed ID

23749683